Icelandirect Acquires SOMA LABS to Expand Pet and Human Supplement Manufacturing

March 20, 2026

Icelandirect, a U.S.-based contract manufacturer and New Heritage Capital portfolio company, acquired SOMA LABS, a New Jersey supplement manufacturer specializing in solid dosage form production. The transaction closed in February 2026 and expands Icelandirect’s capabilities into additional dosage forms, enabling broader end-to-end manufacturing for both human nutrition and pet supplement brands.

Buyers
Icelandirect
Targets
SOMA LABS
Platforms
Icelandirect
Location
New Jersey, United States
Transaction Type
Addon

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.